Home Cart Sign in  
Chemical Structure| 2229025-70-9 Chemical Structure| 2229025-70-9

Structure of WM-3835
CAS No.: 2229025-70-9

Chemical Structure| 2229025-70-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

WM 3835 is a highly potent HBO1 inhibitor and demonstrate its mode of activity as a competitive analogue of acetyl-CoA. It reduced H3K14ac levels and inhibits growth and viability of acyte myeloid leukemia cell lines in vitro.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of WM-3835

CAS No. :2229025-70-9
Formula : C20H17FN2O4S
M.W : 400.42
SMILES Code : O=C(C1=CC(C2=CC=CC=C2)=CC(C)=C1F)NNS(=O)(C3=CC(O)=CC=C3)=O
MDL No. :MFCD34179539
InChI Key :KVJFJJXCBRSCDY-UHFFFAOYSA-N
Pubchem ID :134581412

Safety of WM-3835

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Related Pathways of WM-3835

epigenetics

Isoform Comparison

Biological Activity

Description
WM-3835 is a potent and highly specific inhibitor of HBO1 (KAT7 or MYST2), binding directly to its acetyl-CoA binding site of HBO1 33. It induces apoptosis and inhibits osteosarcoma (OS) cell proliferation, migration, and invasion. WM-3835 exhibits antitumor properties and effectively suppresses the growth of pOS-1 xenografts in mice[1].

In Vitro:

Cell Line
Concentration Treated Time Description References
Rat mesenteric artery endothelial cells (MAECs) 100 nM 24 hours To investigate the effect of WM-3835 on ponatinib-induced endothelial cell senescence and inflammation. Results showed that WM-3835 significantly alleviated ponatinib-induced endothelial cell senescence and inflammatory responses. J Hypertens. 2025 May 1;43(5):827-840
Human osteosarcoma cells (MG63) 5 µM 48 hours WM-3835 significantly inhibited MG63 cell viability and proliferation, and induced apoptosis. Theranostics. 2021 Mar 4;11(10):4599-4615
Human osteosarcoma cells (U2OS) 5 µM 48 hours WM-3835 significantly inhibited U2OS cell viability and proliferation, and induced apoptosis. Theranostics. 2021 Mar 4;11(10):4599-4615
Human osteosarcoma cells (pOS-2) 5 µM 48 hours WM-3835 significantly inhibited pOS-2 cell viability and proliferation, and induced apoptosis. Theranostics. 2021 Mar 4;11(10):4599-4615
Human osteosarcoma cells (pOS-1) 5 µM 48 hours WM-3835 inhibited pOS-1 cell proliferation, migration, and invasion, and induced apoptosis. Theranostics. 2021 Mar 4;11(10):4599-4615
PPC-1 1–25 µM 48 hours WM-3835 dose-dependently inhibited pPC-1 cell survival and proliferation, and caused G1-S phase arrest. Cell Death Dis. 2023 Jan 28;14(1):67
PNSCLC-1 5 µM 48-96 hours WM-3835 significantly inhibited pNSCLC-1 cell viability with an IC50 close to 5 μM and inhibited H3 and H4 histone acetylation Int J Biol Sci. 2022 May 9;18(8):3313-3323
B-ALL cells (NALM-6, REH, RS4;11) 2 µM 96 hours WM-3835 potently inhibited B-ALL cell viability and colony formation, induced G1-S cycle arrest and apoptosis Cell Death Dis. 2023 Aug 4;14(8):498

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
SCID mice Osteosarcoma xenograft model Intraperitoneal injection 10 mg/kg Once daily for 21 days WM-3835 significantly inhibited the growth of osteosarcoma xenografts. Theranostics. 2021 Mar 4;11(10):4599-4615
B-NDG mice B-ALL xenograft model Intraperitoneal injection 10 mg/kg Daily for 2 weeks WM-3835 significantly inhibited tumor growth and prolonged survival Cell Death Dis. 2023 Aug 4;14(8):498
Sprague-Dawley rats Ponatinib-induced hypertension model Intraperitoneal injection 10 mg/kg/day Once daily for 8 days To investigate the effect of WM-3835 on ponatinib-induced hypertension and endothelial dysfunction. Results showed that WM-3835 significantly improved ponatinib-induced hypertension and endothelial dysfunction. J Hypertens. 2025 May 1;43(5):827-840
Nude mice PPC-1 xenograft model Intraperitoneal injection 5 mg/kg Once daily for 14 days WM-3835 significantly inhibited the growth of pPC-1 xenografts, with no apparent toxicities detected. Cell Death Dis. 2023 Jan 28;14(1):67

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.50mL

0.50mL

0.25mL

12.49mL

2.50mL

1.25mL

24.97mL

4.99mL

2.50mL

References

 

Historical Records

Categories